GlassScriptPhysician profile
Daniel Justin Bryan
NPI 1710281035
$4,060.52
in general payments reported to CMS, 2019-2025
16 companies · $1,215 in 2025
The $1,215 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $544 · 2022: $644 · 2023: $624 · 2024: $1,034 · 2025: $1,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,873.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,241.83 | 2023-2025 | |
| Novo Nordisk INC | $477.44 | 2021-2024 | Wegovy |
| Lilly USA, LLC | $442.26 | 2022-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $303.48 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $196.22 | 2021-2022 | |
| Evofem Biosciences, INC. | $97.29 | 2021-2023 | Phexxi |
| Amgen INC. | $80.41 | 2021-2024 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $78.28 | 2022 | |
| Amarin Pharma, INC. | $27.32 | 2021 | |
| Xeris Pharmaceuticals, INC. | $27.28 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $20.87 | 2022 | |
| Galderma Laboratories, L.P. | $20.06 | 2023 | |
| Eisai INC. | $16.61 | 2021 | |
| Pfizer INC. | $15.19 | 2023 | |
| Merz North America, INC. | $12.65 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $3.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.